United Kingdom

People: Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

16 Aug 2019
Change (% chg)

€0.18 (+3.14%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kuhn, Thomas 

Mr. Thomas Kuhn is Chief Executive Officer, and a Director of Poxel SA. He joined Merck Serono in 2000, where he held various positions in clinical development mainly for diabetes products. Between 2004 and 2007, he directed global R&D projects, with two products being in phase 2clinicaltrials, and Life Cycle Management projects, specifically for Glucophage, a diabetes treatment. With the integration of Serono in 2007, he was involved in refining the Merck Serono strategy, which led to the divestment of diabetes as an integrated therapeutic area. He was involved in the establishment of Poxel SA. Mr. Kuhn received his pharmacy degree from University of Lyon I(France) and his MBA from Ashridge University.

Basic Compensation

Total Annual Compensation, EUR 296,678
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR 9,153
Fiscal Year Total, EUR 305,831

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --